{{Rsnum
|rsid=553668
|Gene=ADRA2A
|Chromosome=10
|position=111079821
|Orientation=minus
|GMAF=0.2902
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ADRA2A
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 72.6 | 26.5 | 0.9
| HCB | 28.9 | 52.6 | 18.5
| JPT | 31.0 | 53.1 | 15.9
| YRI | 47.6 | 44.2 | 8.2
| ASW | 45.6 | 45.6 | 8.8
| CHB | 28.9 | 52.6 | 18.5
| CHD | 28.4 | 49.5 | 22.0
| GIH | 56.4 | 31.7 | 11.9
| LWK | 40.9 | 50.9 | 8.2
| MEX | 54.4 | 40.4 | 5.3
| MKK | 48.7 | 37.2 | 14.1
| TSI | 63.7 | 34.3 | 2.0
| HapMapRevision=28
}}{{omim
|id=104210
|desc=ALPHA-2A-ADRENERGIC RECEPTOR; ADRA2A
|rsnum=553668
}}

{{PharmGKB
|RSID=rs553668
|Name_s=
|Gene_s=ADRA2A
|Feature=3' UTR
|Evidence=PubMed ID:19965390
|Annotation=Risk or phenotype-associated allele: A allele. Phenotype: Decreased fasting insulin (p = 0.0004) and impaired insulin secretion during intravenous glucose tolerance test in pancreatic islets isolated from subjects (p = 0.03). Study size: 4681. Study population/ethnicity: Replication study of Swedish control subjects. Significance metric(s): p <= 0.03. Type of association: FA; GN.
|Drugs=
|Drug Classes=
|Diseases=Diabetes Mellitus, Type 2
|Curation Level=Curated
|PharmGKB Accession ID=PA165291594
}}

{{PharmGKB
|RSID=rs553668
|Name_s=
|Gene_s=ADRA2A
|Feature=3' UTR
|Evidence=PubMed ID:19965390
|Annotation=Risk or phenotype-associated allele: A allele. Phenotype: There is increased risk of type 2 diabetes (OR = 1.42, p = 0.04, recessive effect) for carriers of the A allele. Among individuals with low body mass index (<24) or low C-peptide levels (<0.6), there is an increased disease risk in heterozygous subjects (OR = 1.31, p = 0.02, and OR = 1.28, p = 0.03, respectively, using an additive model). These associations were also significant after correcting for rs7903146 genotype in TCF7L2. Study size: 2830 cases and 3740 controls. Study population/ethnicity: Swedish diabetics and unrelated, ethnically-matched non-diabetic controls. Significance metric(s): OR >= 1.28, p <= 0.04. Type of association: CO; GN.
|Drugs=
|Drug Classes=
|Diseases=Diabetes Mellitus, Type 2
|Curation Level=Curated
|PharmGKB Accession ID=PA165291593
}}

{{PharmGKB
|RSID=rs553668
|Name_s=
|Gene_s=ADRA2A
|Feature=3' UTR
|Evidence=PubMed ID:19965390
|Annotation=Risk or phenotype-associated allele: A allele. Phenotype: ADRA2A transcript and protein overexpression in pancreatic islets (p < 0.05 for GG versus GA/AA, and for linear regression of expression versus number of risk alleles). Study size: 32. Study population/ethnicity: Human pancreatic islets isolated from Swedes. Significance metric(s): p < 0.05. Type of association: GN; FA.
|Drugs=
|Drug Classes=
|Diseases=Diabetes Mellitus, Type 2
|Curation Level=Curated
|PharmGKB Accession ID=PA165291595
}}
{{PMID Auto
|PMID=21063237
|Title=Effect of ADRA2A and BDNF gene-gene interaction on the continuous performance test phenotype
}}

{{omim
|id=104210
|rsnum=553668
|variant=0001
}}

{{PMID|17512307|OA=1
}} Association analyses of adrenergic receptor polymorphisms with obesity and metabolic alterations.

{{PMID|19876010|OA=1
}} A preliminary candidate genotype-intermediate phenotype study of satiation and gastric motor function in obesity.

{{PMID|20864182}} ADRA2A polymorphisms and ADHD in adults: possible mediating effect of personality.

{{PMID|21325151|OA=1
}} Genetic variations in the alpha(2A)-adrenoreceptor are associated with blood pressure response to the agonist dexmedetomidine.

{{PMID|21455730|OA=1
}} Variants of ADRA2A are associated with fasting glucose, blood pressure, body mass index and type 2 diabetes risk: meta-analysis of four prospective studies.

{{PMID|22061269}} The rs553668 polymorphism of the ADRA2A gene predicts the worsening of fasting glucose values in a cohort of subjects without diabetes. A population-based study.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs553668
|overall_frequency_n=91
|overall_frequency_d=128
|overall_frequency=0.710938
|n_genomes=52
|n_genomes_annotated=0
|n_haplomes=84
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23153004
|Title=Evaluation of the Association Between the ADRA2A Genetic Polymorphisms and Type 2 Diabetes in a Chinese Han Population
|OA=1
}}

{{PMID Auto
|PMID=23266789
|Title=Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children.
}}

{{PMID Auto
|PMID=23466530
|Title=SCN1AIVS5-91G>A polymorphism is associated with susceptibility to epilepsy but not with drug responsiveness.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}